Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc. (MRTX) Stock Overview

Explore Mirati Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

MRTX●NASDAQ
HealthcareBiotechnology
$58.70
$0.10(0.17%)
U.S. Market is Open · 14:24

Mirati Therapeutics, Inc. (MRTX)

Meyka AI Score

Z

Key Financials

Market Cap4.1B
P/E Ratio-4.45
EPS (TTM)$-12.18
ROE-0.62%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year TargetN/A

MRTX Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Mirati Therapeutics, Inc. (NASDAQ: MRTX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Mirati Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of MRTX on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $N/A for the NASDAQ listing.

Key metrics behind Mirati Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -4.45 and a market capitalization of 4.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of MRTX on the NASDAQ.

Price Performance (NASDAQ: MRTX)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
-0.17%
3-Month Change
3.95%
6-Month Change
55.04%
Year-to-Date (YTD) Change
-0.69%
1-Year Change
29.44%
3-Year Change
-70.69%
5-Year Change
-22.29%
All-Time (Max) Change
732.62%

Contact Information

https://www.bms.com
858 332 3410
3545 Cray Court, San Diego, CA, 92121

Company Facts

5,870 Employees
IPO DateJul 15, 2013
CountryUS

Frequently Asked Questions